HRP20100079T1 - Novi derivati 3-fenilpropionske kiseline za liječenje dijabetesa - Google Patents
Novi derivati 3-fenilpropionske kiseline za liječenje dijabetesa Download PDFInfo
- Publication number
- HRP20100079T1 HRP20100079T1 HR20100079T HRP20100079T HRP20100079T1 HR P20100079 T1 HRP20100079 T1 HR P20100079T1 HR 20100079 T HR20100079 T HR 20100079T HR P20100079 T HRP20100079 T HR P20100079T HR P20100079 T1 HRP20100079 T1 HR P20100079T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound according
- phenyl
- aryl
- heteroaryl
- Prior art date
Links
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 title claims abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 125000001424 substituent group Chemical group 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- 102000000536 PPAR gamma Human genes 0.000 claims abstract 3
- 108010016731 PPAR gamma Proteins 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 8
- -1 ethylenedioxy Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- LBLXMPLHXMJUIA-QFIPXVFZSA-N (2s)-2-(1,3-benzothiazol-2-ylamino)-3-[4-[2-[cyclohexanecarbonyl(methyl)amino]ethoxy]phenyl]propanoic acid Chemical compound C=1C=C(C[C@H](NC=2SC3=CC=CC=C3N=2)C(O)=O)C=CC=1OCCN(C)C(=O)C1CCCCC1 LBLXMPLHXMJUIA-QFIPXVFZSA-N 0.000 claims 1
- SXARVALRXAQNJU-FQEVSTJZSA-N (2s)-2-(1,3-benzoxazol-2-ylamino)-3-[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethoxy)phenyl]propanoic acid Chemical compound C1=CC=C2OC(N[C@@H](CC=3C=CC(OCC=4C=C5OCCOC5=CC=4)=CC=3)C(=O)O)=NC2=C1 SXARVALRXAQNJU-FQEVSTJZSA-N 0.000 claims 1
- MWKYTUMKUUQWIJ-IBGZPJMESA-N (2s)-2-(1,3-benzoxazol-2-ylamino)-3-[4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]phenyl]propanoic acid Chemical compound CC1=NOC(C)=C1COC(C=C1)=CC=C1C[C@@H](C(O)=O)NC1=NC2=CC=CC=C2O1 MWKYTUMKUUQWIJ-IBGZPJMESA-N 0.000 claims 1
- ROXXPZBVTFFVRM-NRFANRHFSA-N (2s)-2-(1,3-benzoxazol-2-ylamino)-3-[4-[2-(2-tert-butyl-5-methyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid Chemical compound O1C(C(C)(C)C)=NC(CCOC=2C=CC(C[C@H](NC=3OC4=CC=CC=C4N=3)C(O)=O)=CC=2)=C1C ROXXPZBVTFFVRM-NRFANRHFSA-N 0.000 claims 1
- ADLDDAWSTHEQDR-DEOSSOPVSA-N (2s)-2-(1,3-benzoxazol-2-ylamino)-3-[4-[2-[5-methyl-2-(3,4,5-trimethoxyphenyl)-1,3-oxazol-4-yl]ethoxy]phenyl]propanoic acid Chemical compound COC1=C(OC)C(OC)=CC(C=2OC(C)=C(CCOC=3C=CC(C[C@H](NC=4OC5=CC=CC=C5N=4)C(O)=O)=CC=3)N=2)=C1 ADLDDAWSTHEQDR-DEOSSOPVSA-N 0.000 claims 1
- ZHECRDLVXOHTHR-QFIPXVFZSA-N (2s)-2-(1,3-benzoxazol-2-ylamino)-3-[4-[2-[cyclohexanecarbonyl(methyl)amino]ethoxy]phenyl]propanoic acid Chemical compound C=1C=C(C[C@H](NC=2OC3=CC=CC=C3N=2)C(O)=O)C=CC=1OCCN(C)C(=O)C1CCCCC1 ZHECRDLVXOHTHR-QFIPXVFZSA-N 0.000 claims 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000005023 xylyl group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL371841A PL371841A1 (pl) | 2004-12-20 | 2004-12-20 | Nowe związki pochodne kwasu 3-fenylopropionowego |
| PCT/EP2005/056839 WO2006067086A1 (en) | 2004-12-20 | 2005-12-16 | New 3-phenylpropionic acid derivatives for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100079T1 true HRP20100079T1 (hr) | 2010-04-30 |
Family
ID=36118603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100079T HRP20100079T1 (hr) | 2004-12-20 | 2010-02-15 | Novi derivati 3-fenilpropionske kiseline za liječenje dijabetesa |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7312338B2 (da) |
| EP (1) | EP1833805B1 (da) |
| JP (1) | JP2008524166A (da) |
| KR (1) | KR100923199B1 (da) |
| CN (1) | CN101084203A (da) |
| AT (1) | ATE457305T1 (da) |
| AU (1) | AU2005318221B2 (da) |
| BR (1) | BRPI0519584A2 (da) |
| CA (1) | CA2588662C (da) |
| CY (1) | CY1110622T1 (da) |
| DE (1) | DE602005019327D1 (da) |
| DK (1) | DK1833805T3 (da) |
| ES (1) | ES2341020T3 (da) |
| HR (1) | HRP20100079T1 (da) |
| IL (1) | IL183563A0 (da) |
| MX (1) | MX2007007452A (da) |
| NO (1) | NO20073736L (da) |
| PL (2) | PL371841A1 (da) |
| PT (1) | PT1833805E (da) |
| RS (1) | RS51228B (da) |
| RU (1) | RU2360906C2 (da) |
| SI (1) | SI1833805T1 (da) |
| UA (1) | UA89807C2 (da) |
| WO (1) | WO2006067086A1 (da) |
| ZA (1) | ZA200704584B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL371841A1 (pl) * | 2004-12-20 | 2006-06-26 | ADAMED Sp.z o.o. | Nowe związki pochodne kwasu 3-fenylopropionowego |
| PL372332A1 (pl) * | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| PL372356A1 (pl) * | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| CN107417707A (zh) * | 2012-05-04 | 2017-12-01 | 萨穆梅德有限公司 | 1H‑吡唑并[3,4‑b]吡啶及其治疗应用 |
| KR20220138654A (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | 당뇨병의 예방 또는 치료용 화합물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58125039A (ja) | 1982-01-21 | 1983-07-25 | Konishiroku Photo Ind Co Ltd | 写真用２当量イエロ−カプラ− |
| US5296486A (en) * | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
| EP0751943A1 (en) | 1994-03-12 | 1997-01-08 | Yuhan Corporation | Triazole compounds and processes for the preparation thereof |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| ES2215719T3 (es) | 1999-09-08 | 2004-10-16 | Glaxo Group Limited | Antagonista ppar oxazol. |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| EP1414785A1 (en) | 2001-07-30 | 2004-05-06 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| JP2005503377A (ja) | 2001-07-30 | 2005-02-03 | ノボ ノルディスク アクティーゼルスカブ | 新規ビニルｎ−（２−ベンゾイルフェニル）−ｌ−チロシン誘導体及び抗糖尿病剤等へのそれらの使用 |
| WO2003074495A1 (en) * | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Hppars activators |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
| PL371841A1 (pl) * | 2004-12-20 | 2006-06-26 | ADAMED Sp.z o.o. | Nowe związki pochodne kwasu 3-fenylopropionowego |
| PL372332A1 (pl) * | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| PL372356A1 (pl) * | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
-
2004
- 2004-12-20 PL PL371841A patent/PL371841A1/pl not_active Application Discontinuation
-
2005
- 2005-12-08 US US11/298,920 patent/US7312338B2/en not_active Expired - Fee Related
- 2005-12-16 UA UAA200708225A patent/UA89807C2/ru unknown
- 2005-12-16 PL PL05826447T patent/PL1833805T3/pl unknown
- 2005-12-16 ES ES05826447T patent/ES2341020T3/es active Active
- 2005-12-16 PT PT05826447T patent/PT1833805E/pt unknown
- 2005-12-16 SI SI200530974T patent/SI1833805T1/sl unknown
- 2005-12-16 RU RU2007127724/04A patent/RU2360906C2/ru not_active IP Right Cessation
- 2005-12-16 RS RSP-2010/0117A patent/RS51228B/sr unknown
- 2005-12-16 AT AT05826447T patent/ATE457305T1/de active
- 2005-12-16 BR BRPI0519584-5A patent/BRPI0519584A2/pt not_active IP Right Cessation
- 2005-12-16 JP JP2007546072A patent/JP2008524166A/ja active Pending
- 2005-12-16 CN CNA200580043841XA patent/CN101084203A/zh active Pending
- 2005-12-16 WO PCT/EP2005/056839 patent/WO2006067086A1/en active Application Filing
- 2005-12-16 DK DK05826447.4T patent/DK1833805T3/da active
- 2005-12-16 KR KR1020077015791A patent/KR100923199B1/ko not_active IP Right Cessation
- 2005-12-16 DE DE602005019327T patent/DE602005019327D1/de active Active
- 2005-12-16 CA CA2588662A patent/CA2588662C/en not_active Expired - Fee Related
- 2005-12-16 EP EP05826447A patent/EP1833805B1/en active Active
- 2005-12-16 MX MX2007007452A patent/MX2007007452A/es active IP Right Grant
- 2005-12-16 AU AU2005318221A patent/AU2005318221B2/en not_active Ceased
-
2007
- 2007-04-26 US US11/740,820 patent/US7919515B2/en not_active Expired - Fee Related
- 2007-05-30 IL IL183563A patent/IL183563A0/en unknown
- 2007-06-04 ZA ZA200704584A patent/ZA200704584B/xx unknown
- 2007-07-18 NO NO20073736A patent/NO20073736L/no not_active Application Discontinuation
-
2010
- 2010-02-15 HR HR20100079T patent/HRP20100079T1/hr unknown
- 2010-03-29 CY CY20101100293T patent/CY1110622T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1110622T1 (el) | 2015-04-29 |
| KR20070097057A (ko) | 2007-10-02 |
| US20070219259A1 (en) | 2007-09-20 |
| AU2005318221B2 (en) | 2009-09-17 |
| SI1833805T1 (sl) | 2010-05-31 |
| EP1833805B1 (en) | 2010-02-10 |
| US20070088061A1 (en) | 2007-04-19 |
| UA89807C2 (ru) | 2010-03-10 |
| ZA200704584B (en) | 2008-10-29 |
| KR100923199B1 (ko) | 2009-10-22 |
| PL1833805T3 (pl) | 2010-04-30 |
| CA2588662C (en) | 2010-12-07 |
| US7312338B2 (en) | 2007-12-25 |
| ES2341020T3 (es) | 2010-06-14 |
| PT1833805E (pt) | 2010-03-31 |
| DK1833805T3 (da) | 2010-05-17 |
| US7919515B2 (en) | 2011-04-05 |
| RU2360906C2 (ru) | 2009-07-10 |
| JP2008524166A (ja) | 2008-07-10 |
| PL371841A1 (pl) | 2006-06-26 |
| NO20073736L (no) | 2007-07-18 |
| MX2007007452A (es) | 2007-11-07 |
| EP1833805A1 (en) | 2007-09-19 |
| DE602005019327D1 (de) | 2010-03-25 |
| WO2006067086A1 (en) | 2006-06-29 |
| AU2005318221A1 (en) | 2006-06-29 |
| BRPI0519584A2 (pt) | 2009-02-17 |
| IL183563A0 (en) | 2007-09-20 |
| CA2588662A1 (en) | 2006-06-29 |
| RS51228B (sr) | 2010-12-31 |
| CN101084203A (zh) | 2007-12-05 |
| RU2007127724A (ru) | 2009-01-27 |
| ATE457305T1 (de) | 2010-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100079T1 (hr) | Novi derivati 3-fenilpropionske kiseline za liječenje dijabetesa | |
| HRP20200549T1 (hr) | Određeni amino-pirimidini, njihovi sastavi, i metode njihove upotrebe | |
| RU2009125019A (ru) | Производные карбоновой кислоты | |
| SI9300452B (sl) | Novi derivati tiazolidindiona | |
| HUP0203532A2 (hu) | HPPAR-alfa aktivátor szubsztituált oxazol- és tiazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HRP20231389T1 (hr) | Spojevi piridazinona i njihove upotrebe | |
| JP2007519735A5 (da) | ||
| JP2009529059A5 (da) | ||
| JP2010540462A5 (da) | ||
| CA2450922A1 (en) | Piperidines for use as orexin receptor antagonists | |
| JP2008513485A5 (da) | ||
| KR940019699A (ko) | 옥사졸리딘디온 유도체, 그의 제조방법 및 용도 | |
| NO20054791D0 (no) | Forbindelser for behandling av stoffskiftesykdommer | |
| HRP20090647T1 (hr) | Novi derivati 3-fenilpropionske kiseline i nihova uporaba kao ppar-gama receptorskih liganada | |
| JP2009528284A5 (da) | ||
| HRP20140588T1 (hr) | Spojevi kondenziranog prstena i njihova uporaba | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| RU2015104962A (ru) | Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков | |
| HUP0203431A2 (hu) | Új heterociklusos vegyületek és sóik, és ezeket tartalmazó gyógyszerkészítmények, valamint felhasználásuk | |
| JP2005527521A5 (da) | ||
| CA2879816C (en) | Methanethione compounds having antiviral activity | |
| ZA200002207B (en) | Substituted pyridine or piperidine compounds, a process for their preparation and pharmaceutical compositions containing them. | |
| KR900018054A (ko) | 헤테로사이클릭구아니딘 5ht₃길항물질 | |
| JP2009509987A5 (da) | ||
| US5128340A (en) | Thiazole derivatives |